Boehringer Ingelheim has made significant strides in their research on progressive pulmonary fibrosis (PPF) with the successful results of their Phase III FIBRONEER™-ILD trial. This trial marks a critical milestone for Nerandomilast, an investigational oral preferential inhibitor of p
The recent Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) to Zai Lab Limited for their drug ZL-1310 marks a significant milestone in the fight against small cell lung cancer (SCLC). This promising Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) is
Allarity Therapeutics, Inc. has announced the expansion of their Phase 2 clinical trial for stenoparib, a dual PARP/Wnt pathway inhibitor, aimed at treating advanced ovarian cancer. Their recent decision seeks to accelerate the drug's clinical development and work towards FDA regulatory
Clinical trials are fundamental to the development of new medical treatments and the advancement of healthcare. However, enrolling and retaining participants in these trials has been a persistent challenge over the years. The perceived difficulty of involvement, alongside high dropout rates, can
The 21st century has seen the pharmaceutical industry face mounting challenges such as escalating competition and pricing pressures. Consequently, developers and manufacturers are pioneering innovative strategies to differentiate their products and instill value, particularly in the saturated
The healthcare investment landscape has undergone significant transformations in recent years, driven by various factors including the COVID-19 pandemic, technological advancements, and strategic shifts within the industry. As we delve into 2024, it is crucial to understand the key trends and